Search Results - "LOKHORST"

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design by Drent, Esther, Poels, Renée, Mulders, Manon J, van de Donk, Niels W C J, Themeli, Maria, Lokhorst, Henk M, Mutis, Tuna

“…Recent clinical advances with chimeric antigen receptor (CAR) T cells have led to the accelerated clinical approval of CD19-CARs to treat acute lymphoblastic…”
Get full text

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study by Kumar, S K, Dimopoulos, M A, Kastritis, E, Terpos, E, Nahi, H, Goldschmidt, H, Hillengass, J, Leleu, X, Beksac, M, Alsina, M, Oriol, A, Cavo, M, Ocio, E M, Mateos, M V, O'Donnell, E K, Vij, R, Lokhorst, H M, van de Donk, N W C J, Min, C, Mark, T, Turesson, I, Hansson, M, Ludwig, H, Jagannath, S, Delforge, M, Kyriakou, C, Hari, P, Mellqvist, U, Usmani, S Z, Dytfeld, D, Badros, A Z, Moreau, P, Kim, K, Otero, P R, Lee, J H, Shustik, C, Waller, D, Chng, W J, Ozaki, S, Lee, J-J, de la Rubia, J, Eom, H S, Rosinol, L, Lahuerta, J J, Sureda, A, Kim, J S, Durie, B G M

“…Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this…”
Get full text

Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab by Nijhof, I S, Groen, R W J, Lokhorst, H M, van Kessel, B, Bloem, A C, van Velzen, J, de Jong-Korlaar, R, Yuan, H, Noort, W A, Klein, S K, Martens, A C M, Doshi, P, Sasser, K, Mutis, T, van de Donk, N W C J

“…Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular…”
Get full text

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network by van de Donk, Niels W C J, Palumbo, Antonio, Johnsen, Hans Erik, Engelhardt, Monika, Gay, Francesca, Gregersen, Henrik, Hajek, Roman, Kleber, Martina, Ludwig, Heinz, Morgan, Gareth, Musto, Pellegrino, Plesner, Torben, Sezer, Orhan, Terpos, Evangelos, Waage, Anders, Zweegman, Sonja, Einsele, Hermann, Sonneveld, Pieter, Lokhorst, Henk M

“…Monoclonal gammopathy of undetermined significance is one of the most common pre-malignant disorders. IgG and IgA monoclonal gammopathy of undetermined…”
Get full text

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma by Lokhorst, Henk M, Plesner, Torben, Laubach, Jacob P, Nahi, Hareth, Gimsing, Peter, Hansson, Markus, Minnema, Monique C, Lassen, Ulrik, Krejcik, Jakub, Palumbo, Antonio, van de Donk, Niels W.C.J, Ahmadi, Tahamtan, Khan, Imran, Uhlar, Clarissa M, Wang, Jianping, Sasser, A. Kate, Losic, Nedjad, Lisby, Steen, Basse, Linda, Brun, Nikolai, Richardson, Paul G

“…Daratumumab was associated with impressive antitumor responses, including complete and very good partial responses, in heavily pretreated patients with…”
Get full text

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond by van de Donk, Niels W. C. J., Janmaat, Maarten L., Mutis, Tuna, Lammerts van Bueren, Jeroen J., Ahmadi, Tahamtan, Sasser, A. Kate, Lokhorst, Henk M., Parren, Paul W. H. I.

“…Summary CD38 is a multifunctional cell surface protein that has receptor as well as enzyme functions. The protein is generally expressed at low levels on…”
Get full text

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A.Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth

“…The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. Here, we present an updated pooled…”
Get full text

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma by Drent, Esther, Groen, Richard W J, Noort, Willy A, Themeli, Maria, Lammerts van Bueren, Jeroen J, Parren, Paul W H I, Kuball, Jürgen, Sebestyen, Zsolt, Yuan, Huipin, de Bruijn, Joost, van de Donk, Niels W C J, Martens, Anton C M, Lokhorst, Henk M, Mutis, Tuna

“…Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression…”
Get full text

A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization by Drent, Esther, Themeli, Maria, Poels, Renée, de Jong-Korlaar, Regina, Yuan, Huipin, de Bruijn, Joost, Martens, Anton C.M., Zweegman, Sonja, van de Donk, Niels W.C.J., Groen, Richard W.J., Lokhorst, Henk M., Mutis, Tuna

“…Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed surface antigens on tumor cells. The low expression of…”
Get full text

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma by Nijhof, Inger S., Casneuf, Tineke, van Velzen, Jeroen, van Kessel, Berris, Axel, Amy E., Syed, Khaja, Groen, Richard W.J., van Duin, Mark, Sonneveld, Pieter, Minnema, Monique C., Zweegman, Sonja, Chiu, Christopher, Bloem, Andries C., Mutis, Tuna, Lokhorst, Henk M., Sasser, A.Kate, van de Donk, Niels W.C.J.

“…The anti-CD38 monoclonal antibody daratumumab is well tolerated and has high single agent activity in heavily pretreated relapsed and refractory multiple…”
Get full text

A gene expression signature for high-risk multiple myeloma by Kuiper, R, Broyl, A, de Knegt, Y, van Vliet, M H, van Beers, E H, van der Holt, B, el Jarari, L, Mulligan, G, Gregory, W, Morgan, G, Goldschmidt, H, Lokhorst, H M, van Duin, M, Sonneveld, P

“…There is a strong need to better predict the survival of patients with newly diagnosed multiple myeloma (MM). As gene expression profiles (GEPs) reflect the…”
Get full text

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma by van de Donk, Niels W.C.J., Moreau, Philippe, Plesner, Torben, Palumbo, Antonio, Gay, Francesca, Laubach, Jacob P., Malavasi, Fabio, Avet-Loiseau, Hervé, Mateos, Maria-Victoria, Sonneveld, Pieter, Lokhorst, Henk M., Richardson, Paul G.

“…Immunotherapeutic strategies are emerging as promising therapeutic approaches in multiple myeloma (MM), with several monoclonal antibodies in advanced stages…”
Get full text

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma by Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W.C.J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A.Kate

“…Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent…”
Get full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial by SONNEVELD, Pieter, SCHMIDT-WOLF, Ingo G. H, WEISEL, Katja C, WITTEBOL, Shulamiet, BOS, Gerard M. J, STEVENS-KROEF, Marian, SCHEID, Christof, PFREUNDSCHUH, Michael, HOSE, Dirk, JAUCH, Anna, DER VELDE, Helgi Van, RAYMAKERS, Reinier, DER HOLT, Bronno Van, SCHAAFSMA, Martijn R, KERSTEN, Marie-Jose, MARWIJK-KOOY, Marinus Van, DUEHRSEN, Ulrich, LINDEMANN, Walter, WIJERMANS, Pierre W, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut M, EL JARARI, Laila, BERTSCH, Uta, SALWENDER, Hans, ZWEEGMAN, Sonja, VELLENGA, Edo, BROYL, Annemiek, BLAU, Igor W

“…We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). In all, 827 eligible patients…”
Get full text

Illegitimate WNT Signaling Promotes Proliferation of Multiple Myeloma Cells by Patrick W. B. Derksen, Tjin, Esther, Meijer, Helen P., Klok, Melanie D., Harold D. Mac Gillavry, Marinus H. J. van Oers, Lokhorst, Henk M., Bloem, Andries C., Clevers, Hans, Nusse, Roel, van der Neut, Ronald, Spaargaren, Marcel, Pals, Steven T., Weissman, Irving L.

“…The unrestrained growth of tumor cells is generally attributed to mutations in essential growth control genes, but tumor cells are also influenced by signals…”
Get full text

CAMPFIRE and Human-Wildlife Conflicts in Local Communities Bordering Northern Gonarezhou National Park, Zimbabwe by Gandiwa, Edson, Heitkönig, Ignas M.A., Lokhorst, Anne M., Prins, Herbert H.T., Leeuwis, Cees

“…Human-wildlife conflicts are a global problem, and are occurring in many countries where human and wildlife requirements overlap. Conflicts are particularly…”
Get full text

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab by VAN DER VEER, Michael S, DE WEERS, Michel, VAN KESSEL, Berris, BAKKER, Joost M, WITTEBOL, Shulamiet, PARREN, Paul W. H. I, LOKHORST, Henk M, MUTIS, Tuna

“…In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug…”
Get full text

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials by SONNEVELD, Pieter, GOLDSCHMIDT, Hartmut, DESAI, Avinash, CAKANA, Andrew, LIU, Kevin, VAN DE VELDE, Helgi, ESSELTINE, Dixie-Lee, MOREAU, Philippe, ROSIÑOL, Laura, BLADE, Joan, JOSE LAHUERTA, Juan, CAVO, Michele, TACCHETTI, Paola, ZAMAGNI, Elena, ATTAL, Michel, LOKHORST, Henk M

“…To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III…”
Get full text

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial by Goldschmidt, H, Lokhorst, H M, Mai, E K, van der Holt, B, Blau, I W, Zweegman, S, Weisel, K C, Vellenga, E, Pfreundschuh, M, Kersten, M J, Scheid, C, Croockewit, S, Raymakers, R, Hose, D, Potamianou, A, Jauch, A, Hillengass, J, Stevens-Kroef, M, Raab, M S, Broijl, A, Lindemann, H W, Bos, G M J, Brossart, P, van Marwijk Kooy, M, Ypma, P, Duehrsen, U, Schaafsma, R M, Bertsch, U, Hielscher, T, Jarari, Le, Salwender, H J, Sonneveld, P

“…The Dutch-Belgian Cooperative Trial Group for Hematology Oncology Group-65/German-speaking Myeloma Multicenter Group-HD4 (HOVON-65/GMMG-HD4) phase III trial…”
Get full text

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial by Broyl, Annemiek, Dr, Corthals, Sophie L, MSc, Jongen, Joost LM, MD, van der Holt, Bronno, PhD, Kuiper, Rowan, BSc, de Knegt, Yvonne, BSc, van Duin, Mark, PhD, el Jarari, Laila, MSc, Bertsch, Uta, MD, Lokhorst, Henk M, Prof, Durie, Brian G, MD, Goldschmidt, Hartmut, Prof, Sonneveld, Pieter, Prof

“…Summary Background Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of…”
Get full text